Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human serum albumin (HSA) is the principal extracellular carrier of exchangeable Cu(II) in blood and binds copper mainly at its N-terminal ATCUN site, contributing substantially to the plasma Cu(II) pool and delivery to tissues[6]. Hepatocytes and other cells take up copper from Cu–albumin; evidence indicates cells recognize Cu–albumin and may preferentially bind a ternary Cu–albumin–histidine complex before releasing albumin/histidine and transporting copper across the membrane[2][5]. In pharmacology, HSA’s labile Cu(II) pool serves as a metal source for certain anticancer thiosemicarbazones, which chelate Cu(II) from HSA’s N-terminus and can form ternary conjugates with HSA, affecting drug activity and behavior[8][4]. Numerous synthetic Cu(II) complexes and chelators interact with serum albumin, with binding often occurring at defined albumin drug-binding sites and influencing complex stability and protein structure[1][3]. Overall, “albumin–copper complex formation” describes a physiological carrier–metal interaction rather than a discrete drug target, but it is crucial for copper homeostasis and can modulate the pharmacology of copper-interacting therapeutics[6][8][5][2][1][3].
For thiosemicarbazones: chelation of Cu(II) from the N-terminal Cu-binding site of HSA, formation of Cu(II)–TSC complexes and ternary HSA conjugates (likely via histidine), influencing anticancer activity and pharmacology[8][4]. Cellular uptake context: cells recognize Cu–albumin and preferentially a ternary Cu–albumin–histidine complex; albumin/histidine are released and copper is transported across the membrane after binding to the cell surface[2]. Multiple routes for cellular acquisition of copper from albumin and α2-macroglobulin; hepatic uptake partly via CTR1 for α2-macroglobulin, with additional unidentified systems for albumin-derived copper[5].
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human serum albumin copper binding (N-terminal ATCUN site) (HSA Cu(II)-binding site (ATCUN)).